Shanghai RAAS first-half revenue and net profit both decline, goodwill of 8.199 billion yuan weighs on the company

Earnings

โดย 进口白蛋白营业收入为14.35亿元·

Summary · why it matters

Shanghai RAAS achieved operating revenue of 3.209 billion yuan in the first half of 2026, down 18.79% year on year, while net profit attributable to the parent company was 661 million yuan, down 35.80% year on year. The blood products industry was broadly under pressure over the same period, with companies such as Pacific Shuanglin Bio-pharmacy, Boya Bio-pharmaceutical, and Weiguang Biological reporting declines of varying degrees, and China National Biotec Group expecting net profit attributable to the parent company to fall by more than 50% year on year. Shanghai RAAS carried goodwill of as much as 8.199 billion yuan on its books, including about 3 billion yuan of goodwill formed from the acquisition of a 100% stake in Nanyue Biopharmaceutical for 4.2 billion yuan in cash in March 2025. The company's self-developed, world-first hemophilia monoclonal antibody SR604 is still in the preparation stage for Phase III clinical trials and has not yet contributed commercial revenue. On August 25, Shanghai RAAS announced that chief financial officer Chen Leqi had resigned for personal reasons and would be succeeded by Jiang Lan, who has worked in the Haier system for more than twenty years.

Shanghai RAAS Blood Products Co Ltd Class A ▼